MedTrace Logo

Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma

NCT02583477 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2019-08-14

Study results available
· View outcomes & findings →

Summary

A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Conditions

Interventions

DRUG

MEDI4736 in combination with nab-paclitaxel and gemcitabine

MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion

DRUG

MEDI4736 in combination with AZD5069

MEDI4736 via IV infusion and oral AZD5069

Sponsors & Collaborators

Principal Investigators

  • Jeff Evans, M.D · Beatson Institute, University of Glasgow, Garscrube Estate, Switchback Rd. Glasgow, UK, G61 1BD

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-25
Primary Completion
2018-07-09
Completion
2018-07-09
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583477 on ClinicalTrials.gov